55919-82-9

Basic information

• Product Name: 5-Iodo-1H-indazole
• Synonyms: 5-IODO (1H)INDAZOLE;5-IODOINDAZOLE;1H-Indazole, 5-iodo-
• CAS NO: 55919-82-9
• Molecular Formula: C₇H₅IN₂
• Molecular Weight: 244.03
• Product Categories: pharmacetical
• Mol File: 55919-82-9.mol
• Article Data: 19

Chemical Properties

• Melting Point: 156 °C
• Boiling Point: 358.187 °C at 760 mmHg
• Flash Point: 170.426 °C
• Appearance: Yellow to brown to purple/Crystalline Powder
• Density: 2.082g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.788
• Storage Temp.: 2-8°C(protect from light)
• PKA: 12.87±0.40(Predicted)
• CAS DataBase Reference: 5-Iodo-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Iodo-1H-indazole(55919-82-9)
• EPA Substance Registry System: 5-Iodo-1H-indazole(55919-82-9)

Safety Data

• Hazardous Substances Data: 55919-82-9(Hazardous Substances Data)

Usage

Chemical Properties

Solid

InChI:InChI=1/C7H5IN2/c8-6-1-2-7-5(3-6)4-9-10-7/h1-4H,(H,9,10)

Upstream product

• 1055974-14-5 5-iodo-1-(phenylsulfonyl)-1H-indazole 
• 5401-94-5 5-nitroindazole 
• 850363-46-1 1-acetyl-5-iodo-1H-indazole 
• 53857-57-1 5-bromo-1H-indazole 
• 19335-11-6 1H-indazol-5-ylamine 
• 1228823-20-8 C₇H₅N₄⁽¹⁺⁾*Cl^(1-) 
• 13194-68-8 4-iodo-2-methylaniline 

Downstream Products

• 351456-48-9 3,5-diiodo-1H-indazole 

Relevant articles and documents

Visible-Light-Mediated N-Desulfonylation of N-Heterocycles Using a Heteroleptic Copper(I) Complex as a Photocatalyst

A photoredox protocol that uses a heteroleptic Cu (I) complex, [Cu(dq)(BINAP)]BF4, has been developed for the photodeprotection of benzenesulfonyl-protected N-heterocycles. A range of substrates was examined, including indazoles, indoles, pyrazoles, and benzimidazole, featuring both electron-rich and electron-deficient substituents, giving good yields of the N-heterocycle products with broad functional group tolerance. This transformation was also found to be amenable to flow reaction conditions.

SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

COMPOUND USEFUL AS A C-MET INHIBITOR

The present invention relates to a c-Met inhibitor (disclosed herein) or a pharmaceutically acceptable salt thereof useful in treating cancer mediated by activity of c-Met receptors.